Atlas Trials

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Clinical trial NCT04551963 · COMPLETED

Trial details

NCT number
NCT04551963
Sponsor
BeiGene
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
B-cell Malignancies
Start date
2020-11-15
Primary completion
2022-02-21
Enrollment
26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.